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Epidemiology 
Portugal 
*GLOBOCAN Report 2012 - International Agency for Research on Cancer 
• 7129 new cases of Colorectal Cancer * 
 
• 1/3  are rectal cancers 
 





 25% of patients have metastatic disease at presentation  
 
 30% develop metastases during the course of their disease 
 
 The liver is the most common site of metastatic disease,  
 
• Involved in 80 % of cases 
 




 Tzeng CW, Aloia TA. Colorectal liver metastases. J Gastrointest Surg. 2013  
Frankel TL, D’Angelica MI. Hepatic resection for colorectal metastases. J Surg Oncol. 2014 












Resected R0 -  5 year survival ranges between 27% to 74%  






Results of hepatic resection for mets CCR 
n 
Survival  
at 5 Years % 
median survival , M 
Hughes, KS; 1986 607 33 NR 
Scheele, J; 1995 434 33 40 
Nordlinger, B; 1996 1568 28 NR 
Jamison, RL; 1997 280 27 33 
Fong, Y; 1999 1001 37 42 
Iwatsuki, S; 1999 305 32 NR 
Choti, M; 2002 133 58 NR 
Abdalla, E; 2004 190 58 NR 
Fernandez, FG; 2004 100 58 NR 
Wei, AC; 2006 423 47 NR 
Aloia TA; 2006 150 71 
Rees, M; 2008 929 36 42.5 
de Jong, M; 2009 1669 47 36 




Resected R0 -  5 year survival ranges between 27% to 74%  
















 When patients with unresectable disease are downstaged to complete 
resection, long-term data support 5 and 10-year survival are similar to 







Liver metastases in colorectal cancer 
Liver metastases 
Resectable 
20% to 25% 
Nonresectable 
75% to 80% 
Survival benefit 
27% to 74 % at 5 Y 
downstage 
Resectable 




































CT - scan of the abdomen and chest 
 
MRI - if small lesions, a fatty liver or preop CT  
 
PET - in case of tumor recurrence 
  - in patients with a previous liver resection 











liver function evaluation 
Two management strategies (to improve resectability.) 
 
 
- Optimize the FLR 
 















- Shrink tumors  
 
Conversion chemotherapy,  
 











 Systemic Chemotherapy 
 
 










• Modern chemotherapeutic agents 
 (Oxaliplatin, Irinotecan … and new regimens FOLFOX, FOLFIRI …) 
 
 - tumor response rates of >50% 
 
 - 6-month stable disease 90–95 % 
 








• N= 872 
 













Ann Surg Oncol. 2001 
5-year survival 39 % 
Tumor response rate -patients with unresectable CRLM 
Curr Oncol Rep (2014) 16:407 
  
 
• Modern preop CT allows complete resection in 12-35% of patients 
 
 
• A strong correlation between the response rates and the resection rates 








-5 year OS (40–50 %)     
-similar to upfront resectable patients  








• Liver mets larger than 3 mm over 80% of their blood irrigation is by hepatic artery 
 
 
• Normal hepatocytes derive their blood supply from the PV (75%)  
 
 











• This directed therapy allows an increased amount of cytotoxic drugs without 








• This therapy can be used in combination with systemic chemotherapy 
 
 




• 49 patients with unresectable CRLM 
 
 
• combined HAIP and systemic CT including bevacizumab 
 
 
• 47% achieved conversion to resection at a median of 6 months from 
treatment initiation 
 
• 3-year OS – resected patients 80% / not resection26% 
Ann Surg. 2015 February ; 261(2): 353–360. 
Two management strategies (to improve resectability.) 
 
 
- Optimize the FLR 
 















- Shrink tumors  
 
Conversion chemotherapy,  
 
























local ablation techniques 
 
Resection of all detectable lesions with tumor-free margins 








• Evaluation of the underlying parenchymal status and function 
 
 
• Evaluation of liver tumors (the proximity to critical structures) 
 
 







Parenchymal-sparing liver surgery 





 This technique allow radical but conservative liver resections 
 
 Avoiding the unnecessary sacrifice of functional parenchyma  
 
 Reducing the risk of developing postoperative liver failure 
 
 Avoiding the necessity of PVE / two stage heptectomy  
 
with equal or better perioperative and long-term outcomes than non-PSLS 
 
  
- A profound knowledge of liver patient’s anatomy  
- Expert IOUS skills  







 “Prophylactic” large resections were useless in preventing intra or 
extra-hepatic recurrence 
 
• increased patient risk 
 
• less chances of future repeated resection 
 




Kokudo N; Am J Surg 2001; 181: 153-159 
Tanaka K; World J Surg 2008; 32: 2057-2069 
S7 resection 
S7 
partial resection of RHV 
reconstruction by running suture 
S4a 





 Introduced in the 1980s by Makuuchi 
 
 
 Tumor is technically resectable but the FRL is too small 
 
 
 Is embolized the PV supplying the portion of liver to be resected 
 
 Induce ipsilateral atrophy and contralateral compensatory hypertrophy of the 
FRL up to 40% over a median period of approximately 4 weeks* 
*Azoulay, Ann. Surg. April 2000 Vol. 231, No. 4, 








 Surgery 2 to 6 weeks after PVE  
 
 
 Resectability 60% to 82% 
 
 - progression of hepatic or extrahepatic disease  
 





Br J Surg. 2010 Feb;97(2):240-50. 
n = 364 hepatectomias major 
 
PVE  = 67 (18%) 
 









    
   PVE in bilobar disease  
 







Kokudo N  et al, Hepatology, 2001;34:267-72. 
Two stage hepatectomy 
Two stage hepatectomy 
 






• the first stage - clearing the FLR 
 
• PVE to increase the volume of the tumor-free FLR.  
 
• second stage - resection of the remaining disease 
 
 
The second stage resection is completed in 69-77% of patients ** 
 
Patients who complete two-stage procedure had an overall 5 Y survival of 42% 
**Oncology, Vol 5, No 5 October 2014  
Annals of surgery 248, dec 2008 
Two stage hepatectomy-strategy 
 
 
 Preop CT 
First-stage resection + PVE 





René Adam, MD, Ann Surg. 2000 December; 232(6): 777–785.  
Two-Stage Hepatectomy: A Planned Strategy to Treat Irresectable Liver Tumors 
Wicherts, Ann Surg 2008;248: 994–1005) 








• Is a novel two-stage technique for optimizing FLR 
 
• First stage -Portal vein ligation is combined with an in situ liver transection 
 
• Results in a pronounced short-term parenchymal hypertrophy over 
approximately 1 week 
 
• Second stage (1 week), a second laparotomy  to remove the pre-divided liver  
 
ALPPS - Associated Liver Partition and Portal vein ligation for Staged hepatectomy  
 
• The increase in FLR with ALPPS ranges form  63-87%  
 
 
• Advantage of ALPPS over PVE is the short interval to completion surgery 
  
 hypertrophy of the FLR - in less than   10 days (ALPPS) 




 Morbidity 53-71% /  mortality of 0-22%  
 
 The benefit of ALPPS over conventional PVE is heavily debated 
 
J Gastrointest Oncol 2014;5(5):374-38 




 RFA thermally ablate tumors 
 










 Patients who are not candidates for surgical resection (co-morbidities) 
 
 
 May be used in combination with resection in order to optimize FLR 
Journal of surgical oncology 2006;93:8-12 
Locoregional Therapies - RFA 
 
 





 Tumors greater than 30 mm  (high recurrence rate) 
 
 
 Contact with major biliary structures (risk for bile duct stricture and fistula) 
 
 





 141 patients treated with multiple resections 
 
 95 patients treated with  ablation +  resection techniques 
 
 5-year OS was statistically similar - ablation-resection (56 %) 
        - multiple resection (49 %) 
 
 
JAMA Surg. 2013 July ; 148(7): 597–601 












 comparison of results in 2 prospective studies SECA / NORDIC VII 
 - CRC nonresectable metástases 
 - liver-only metástases 
 
 SECA study - patients undergoing liver transplantation  
 
 NORDIC VII study  - patients receiving chemotherapy 
      - Nordic FLOX with or without cetuximab  
 












5-year OS  
-56% in patients undergoing liver transplantation 
-9% in patients starting firstline chemotherapy 








 Selecting patients for liver transplantation based on  
 
• CEA <80 μg/L 
• metastases < 5.5 cm 
• no progressive disease at the time of transplantation 
• more than 2 years from diagnosis of CRC 
 
 
May be obtained a 5-year OS rate of 75% 
Liver metastases in colorectal cancer 
Liver metastases 
Resectable 
20% to 25% 
Nonresectable 
75% to 80% 
Survival benefit 
27% to 74 % at 5 Y 
downstage 
Resectable 
20% to 30% 





• Surgical resection remains the treatment of choice for resectable CLM 
 
 




• Treating hepatic metastases requires a knowledge of all treatment options 
 
 
• Patients with unresectable disease are downstaged to complete resection, long-
term data support 5 and 10-year survival are similar to upfront resectable patients 
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